NRXP Earnings
Friday, May 15 2026
EPS Estimate
$-0.02
$-0.02 – $-0.02
Revenue Estimate
$52M
Current Price
$2.94
Our Position
bearishNRXP short interest surges 29% to 3.25M
structured data
est. revisions stable
The surge in short interest indicates growing skepticism on the near-term path, potentially clashing with bullish analyst buy ratings and upcoming FDA decision in summer 2026.
Watch: Monitor FDA approval news and commercial traction in HOPE Therapeutics clinics for signs of shift in sentiment or short squeeze potential.
Data Signal Summary
1 bullish
3 bearish
Estimates down -450%
Put/call 15.2 (bearish skew)
Price downtrend
Insider buying
Key Context
Analyst Consensus
mixed
Insider Activity
buying
Price Trend
downtrend
From 52w High
-8.1%
Est. Revisions (30d)
-450.0% 0up/1dn
Analyst Target (mean)
$38 $25–$49 +1201%
Options P/C Ratio
15.22
Est. Dispersion
0% 1 analysts
Recent Activity
insider trades
1 transaction
Buy
·
JAVITT JONATHAN C (Chairman of the Board)
·40,000 shares
·$65,600
analyst ratings
4 ratings
HC Wainwright & Co.
→Buy
1d ago
Ascendiant Capital
→Buy
1d ago
D. Boral Capital
→Buy
5d ago
D. Boral Capital
→Buy
8d ago
Explore more
